World's Best Scientists 2026 revealed!

D-Index & Metrics

Neuroscience

D-Index
83
Citations
30071
World Ranking
1428
National Ranking
718

Overview

Adam S. Fleisher is affiliated with Avid Radiopharmaceuticals in the United States, focusing on medical research in the field of medicine. Their scholarly work is largely concentrated on dementia and cognitive impairment, particularly Alzheimer's disease research and treatments. The research spans several specialized areas including psychiatry and mental health, physiology, cognitive neuroscience, molecular biology, and radiology, nuclear medicine, and imaging.

The scientist's publication record includes notable recent papers such as:

  • Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease, 2020, Nature Communications
  • Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes, 2020, JAMA Neurology
  • Functional brain architecture is associated with the rate of tau accumulation in Alzheimer's disease, 2020, Nature Communications
  • Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum, 2022, JAMA Neurology
  • Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical Symptoms, and Genetics Among Patients With Late-Life Depression, 2022, JAMA Psychiatry

Frequent co-authors collaborate extensively with Adam S. Fleisher. These researchers include John C. Morris, Laurel Beckett, Michael Donohue, Clifford R. Jack, and Robert C. Green.

The main venues where the scientist's research has appeared include:

  • Nature Communications
  • JAMA Neurology
  • Scientific Reports
  • GeroScience
  • Alzheimer's & Dementia

The core topics covered in Adam S. Fleisher's research include:

  • Dementia and Cognitive Impairment Research
  • Alzheimer's disease research and treatments
  • Functional Brain Connectivity Studies
  • Advanced Neuroimaging Techniques and Applications
  • Bioinformatics and Genomic Networks
  • Genetic Associations and Epidemiology
  • S100 Proteins and Annexins

Within their disciplines, the scientist's work spans multiple subfields that reflect the interdisciplinary nature of their research, incorporating elements of molecular biology and advanced imaging techniques. This comprehensive approach supports the exploration of neurodegenerative mechanisms and clinical biomarkers, particularly related to Alzheimer's disease diagnostics and neuropathology.

Best Publications

  • The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods.

    Clifford R. Jack;Matt A. Bernstein;Nick C. Fox;Paul Thompson

  • Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.

    Willemijn J. Jansen;Rik Ossenkoppele;Dirk L. Knol;Betty M. Tijms

  • Use of Florbetapir-PET for Imaging β-Amyloid Pathology

    Christopher M. Clark;Julie A. Schneider;Barry J. Bedell;Thomas G. Beach

  • Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis

    Y. Iturria-Medina;R. C. Sotero;P. J. Toussaint;J. M. Mateos-Pérez

  • Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study

    Christopher M Clark;Michael J Pontecorvo;Thomas G Beach;Barry J Bedell

  • Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis.

    Rik Ossenkoppele;Willemijn J Jansen;Gil D Rabinovici;Dirk L Knol

  • Four distinct trajectories of tau deposition identified in Alzheimer’s disease

    Jacob W Vogel;Alexandra L Young;Neil P Oxtoby;Ruben Smith

  • Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study

    Eric M Reiman;Yakeel T Quiroz;Yakeel T Quiroz;Adam S Fleisher;Kewei Chen

  • Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease

    Jacob W. Vogel;Yasser Iturria-Medina;Olof T. Strandberg;Ruben Smith

  • Phase 2 Safety Trial Targeting Amyloid β Production With a γ-Secretase Inhibitor in Alzheimer Disease

    Adam S. Fleisher;Rema Raman;Eric R. Siemers;Lida Becerra

  • Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease

    Unknown

  • Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes

    Adam S Fleisher;Michael J Pontecorvo;Michael D Devous;Ming Lu

  • Using Positron Emission Tomography and Florbetapir F 18 to Image Cortical Amyloid in Patients With Mild Cognitive Impairment or Dementia Due to Alzheimer Disease

    Adam S. Fleisher;Kewei Chen;Xiaofen Liu;Auttawut Roontiva

  • Alzheimer’s Prevention Initiative: A Plan to Accelerate the Evaluation of Presymptomatic Treatments

    Eric M. Reiman;Jessica B.S. Langbaum;Adam S. Fleisher;Richard J. Caselli

  • Learning brain connectivity of Alzheimer's disease by sparse inverse covariance estimation.

    Shuai Huang;Jing Li;Liang Sun;Jieping Ye

  • Sex, Apolipoprotein E ε4 Status, and Hippocampal Volume in Mild Cognitive Impairment

    Adam Fleisher;Michael Grundman;Clifford R. Jack;Ronald C. Petersen

  • Phase 3 Trial of Flutemetamol Labeled With Radioactive Fluorine 18 Imaging and Neuritic Plaque Density

    Craig Curtis;Jose E. Gamez;Upinder Singh;Carl H. Sadowsky

  • Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer's pathology.

    Taylor W. Schmitz;R. Nathan Spreng;Michael W. Weiner;Paul Aisen

  • CATEGORICAL AND CORRELATIONAL ANALYSES OF BASELINE FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY IMAGES FROM THE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE (ADNI)

    Jessica B.S. Langbaum;Kewei Chen;Wendy Lee;Cole Reschke

  • Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment.

    A. S. Fleisher;B. B. Sowell;C. Taylor;A. C. Gamst

  • Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE

    Alzheimer's Disease Neuroimaging Initiative

  • Resting-state BOLD networks versus task-associated functional MRI for distinguishing Alzheimer's disease risk groups.

    Adam S. Fleisher;Ayesha Sherzai;Curtis Taylor;Jessica B.S. Langbaum

Frequent Co-Authors

Eric M. Reiman
Eric M. Reiman Arizona State University
Gene E. Alexander
Gene E. Alexander University of Arizona
William J. Jagust
William J. Jagust University of California, Berkeley
Michael W. Weiner
Michael W. Weiner University of California, San Francisco
Robert A. Koeppe
Robert A. Koeppe University of Michigan–Ann Arbor
Reisa A. Sperling
Reisa A. Sperling Brigham and Women's Hospital
Clifford R. Jack
Clifford R. Jack Mayo Clinic
Paul M. Thompson
Paul M. Thompson University of Southern California
Anders M. Dale
Anders M. Dale J. Craig Venter Institute
James B. Brewer
James B. Brewer University of California, San Diego

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Adam S. Fleisher

Trending Scientists